Results 1 to 10 of about 12,134 (165)

Angioedema associated with dipeptidyl peptidase-IV inhibitors. [PDF]

Clin Mol Allergy, 2021
Abstract Background Dipeptidyl peptidase-IV (DPP-IV) inhibitors, also known as gliptins, are a class of oral antidiabetic agents. Postmarketing reports have documented the occurrence of angioedema in patients treated with gliptins and it was found that these drugs increased the risk of angioedema in patients concurrently
Cassano N, Nettis E, Di Leo E, Ambrogio F, Vena GA, Foti C.   +5 more
europepmc   +5 more sources

Identification of potential dipeptidyl peptidase IV inhibitors from the ConMedNP library by virtual screening, and molecular dynamics methods [PDF]

Heliyon
In this study, we screened novel dipeptidyl peptidase IV (DPP4) inhibitors from the ConMedNP library consisting of 3507 molecules. Interestingly, molecular docking, ADMET, and the anti-diabetic activity predictions suggest that three molecules, namely ...
Hans Merlin Tsahnang Fofack, Maraf Mbah Bake, Simon Petry, Baruch A. Ateba, Pascal Amoa Onguéné, Haydar Mohammad-Salim, Fidele Ntie-Kang, Luc Meva'a Mbaze, Serhii Vakal, Cyril A Kenfack   +9 more
doaj   +2 more sources

The roles of dipeptidyl peptidase-4 inhibitors in prognosis of COVID-19 infection in patients with type 2 diabetes mellitus

Journal of Research in Medical Sciences, 2022
Background: COVID-19 is responsible for the latest pandemic. Dipeptidyl peptidase-4 (DPP-4) is one of the cellular receptors of interest for coronavirus. The aim of this study was to assess the roles of DPP-4 inhibitors in prognosis of COVID-19 infection
Mohammad Sadidi, Ahad Zare, Mehrdad Nasrollahzadehsabet, Farzaneh Dastan, Ali Mosadegh Khah, Milad Jafari Asheyani   +5 more
doaj   +1 more source

Increased Risk of Hospitalization for Heart Failure with Newly Prescribed Dipeptidyl Peptidase-4 Inhibitors and Pioglitazone Using the Korean Health Insurance Claims Database [PDF]

Diabetes & Metabolism Journal, 2015
BackgroundWe assessed the association of dipeptidyl peptidase 4 inhibitors (DPP4i) with hospitalization for heart failure (HF) using the Korean Health Insurance claims database.MethodsWe collected data on newly prescribed sitagliptin, vildagliptin, and ...
Sunghwan Suh, Gi Hyeon Seo, Chang Hee Jung, Mee-Kyoung Kim, Sang-Man Jin, You-Cheol Hwang, Byung-Wan Lee, Jae Hyeon Kim   +7 more
doaj   +1 more source

Dipeptidyl Peptidase (DPP)-IV Inhibitors with Antioxidant Potential Isolated from Natural Sources: A Novel Approach for the Management of Diabetes

Pharmaceuticals, 2021
Type 2 diabetes mellitus (T2DM) is characterized by hyperglycemia that is predominantly caused by insulin resistance or impaired insulin secretion, along with disturbances in carbohydrate, fat and protein metabolism.
Anand-Krishna Singh, Dhananjay Yadav, Neha Sharma, Jun-O Jin   +3 more
doaj   +1 more source

Brown goat yogurt: Metabolomics, peptidomics, and sensory changes during production

Journal of Dairy Science, 2023
: Brown goat milk products have gained popularity for their unique taste and flavor. The emergence of chain-reversal phenomenon makes the design and development of goat milk products gradually tend to a consumer-oriented model.
R. Zhang, W. Jia
doaj   +1 more source

Increasing Age Associated with Higher Dipeptidyl Peptidase-4 Inhibition Rate Is a Predictive Factor for Efficacy of Dipeptidyl Peptidase-4 Inhibitors [PDF]

Diabetes & Metabolism Journal, 2022
Background It is not known which type 2 diabetes mellitus (T2DM) patients would most benefit from dipeptidyl peptidase-4 (DPP-4) inhibitor treatment.
Sangmo Hong, Chang Hee Jung, Song Han, Cheol-Young Park   +3 more
doaj   +1 more source

Dipeptidyl peptidase IV, aminopeptidase N and DPIV/APN-like proteases in cerebral ischemia

Journal of Neuroinflammation, 2012
Background Cerebral inflammation is a hallmark of neuronal degeneration. Dipeptidyl peptidase IV, aminopeptidase N as well as the dipeptidyl peptidases II, 8 and 9 and cytosolic alanyl-aminopeptidase are involved in the regulation of autoimmunity and ...
Röhnert Peter, Schmidt Werner, Emmerlich Patrick, Goihl Alexander, Wrenger Sabine, Bank Ute, Nordhoff Karsten, Täger Michael, Ansorge Siegfried, Reinhold Dirk, Striggow Frank   +10 more
doaj   +1 more source

A Multicentre, Multinational, Open-Label, 52-Week Extension Study of Gemigliptin (LC15-0444) Monotherapy in Patients with Type 2 Diabetes Mellitus [PDF]

Diabetes & Metabolism Journal, 2021
The purpose of this extension study was to assess the long-term efficacy and safety of gemigliptin 50 mg in patients with type 2 diabetes mellitus (T2DM).
Sae Jeong Yang, Kyung Wan Min, Sandeep Kumar Gupta, Joong Yeol Park, Vyankatesh K. Shivane, Pankaj Kumar Agarwal, Doo Man Kim, Yong Esong Kim, Sei Hyun Baik   +8 more
doaj   +1 more source

Comparison of Efficacies of a Dipeptidyl Peptidase IV Inhibitor and α-Glucosidase Inhibitors in Oral Carbohydrate and Meal Tolerance Tests and the Effects of Their Combination in Mice

Journal of Pharmacological Sciences, 2007
E3024 (3-but-2-ynyl-5-methyl-2-piperazin-1-yl-3,5-dihydro-4H-imidazo[4,5-d]pyridazin-4-one tosylate) is a dipeptidyl peptidase IV (DPP-IV) inhibitor. Since the target of both DPP-IV inhibitors and α-glucosidase inhibitors is the lowering of postprandial ...
Kazuto Yamazaki, Takashi Inoue, Nobuyuki Yasuda, Yoshiaki Sato, Tadashi Nagakura, Osamu Takenaka, Richard Clark, Takao Saeki, Isao Tanaka   +8 more
doaj   +1 more source